top of page

FDA approves Sanofi's Infilbray as first treatment for neurological symptoms of type 3 Gaucher disease

Immagine del redattore: nuaxia
nuaxia
1 giorno fa
Tempo di lettura: 2 min

Sanofi's oral glucosylceramide synthase inhibitor becomes the first FDA-approved medicine specifically targeting neurological symptoms of type 3 Gaucher disease, following evidence from a 52-week randomised study.


The US Food and Drug Administration approved Infilbray (venglustat) on 18 November 2026 for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, introducing a treatment designed to address neurological manifestations of this rare inherited disorder.


The approval was supported by a 52-week randomised study involving 43 patients aged 12 years and older whose systemic disease had been stabilised with enzyme replacement therapy, with Infilbray demonstrating improvement on a combined neurological assessment; the medicine is not a cure and carries important psychiatric and reproductive safety considerations.

Field

Content

Company

Sanofi

Medicine

Infilbray (venglustat)

Regulatory Authority

US Food and Drug Administration

Approval Date

18 November 2026

Approval Type

New medicine approval for neurological symptoms

Therapeutic Area

Rare neurological and lysosomal storage diseases

Indication

Neurological symptoms of type 3 Gaucher disease

Eligible Population

Adults and children weighing at least 15 kg

Drug Mechanism

Glucosylceramide synthase inhibition

Administration

Oral

Blood-Brain Barrier

Medicine crosses the blood-brain barrier

Supporting Study

52-week randomised study involving 43 patients aged 12 years and older with systemic disease stabilised on enzyme replacement therapy

Efficacy Findings

Improvement on a combined neurological assessment compared with continued enzyme replacement therapy

Existing Treatment Context

Enzyme replacement therapy addresses systemic manifestations but has limitations for neurological disease

Safety Considerations

Psychiatric adverse effects and potential reproductive risks

Regulatory Significance

First FDA-approved treatment specifically addressing neurological symptoms of type 3 Gaucher disease; not a cure

Primary Source

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease


Discover how nuaxia can support your next medical education initiative:

 
 
 

Commenti

Valutazione 0 stelle su 5.
Non ci sono ancora valutazioni

Aggiungi una valutazione
bottom of page